HFSA 2018: Sacubitril/Valsartan Is Associated With Improved Disease-Specific Health Status in HFrEF
Approximately 20% of patients with HFrEF derive a very large, early improvement in health status after initiation of the drug.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.